XORTX Announces Grant of European Patent
XORTX Therapeutics (NASDAQ: XRTX) has announced the granting of a European patent for 'Xanthine Oxidase Inhibitor Formulations.' The patent covers compositions and methods for formulating the company's proprietary XOI formulations to treat conditions related to high uric acid, including gout, renal, and cardiovascular diseases.
This patent strengthens XORTX's intellectual property portfolio in the EU and provides broader protection for their first-in-class gout program and autosomal dominant polycystic kidney disease (ADPKD) program. The patent specifically addresses health consequences arising from uric acid crystal formation due to hyperuricemia.
With this addition, XORTX now holds five granted patents in the United States and/or EU, covering compositions and uses of uric acid lowering agents for treating gout, hyperuricemia consequences, and progressive kidney disease.
XORTX Therapeutics (NASDAQ: XRTX) ha annunciato il rilascio di un brevetto europeo per le «Formulazioni di Inibitori della Xantina Ossidasi». Il brevetto copre composizioni e metodi per formulare le esclusive formulazioni XOI dell'azienda, destinate al trattamento di condizioni legate all'elevato acido urico, tra cui gotta, malattie renali e cardiovascolari.
Questo brevetto rafforza il portafoglio di proprietà intellettuale di XORTX nell'UE e offre una protezione più ampia per il loro programma innovativo contro la gotta e il programma per la malattia renale policistica autosomica dominante (ADPKD). Il brevetto si concentra in particolare sulle conseguenze sanitarie derivanti dalla formazione di cristalli di acido urico causata dall'iperuricemia.
Con questa aggiunta, XORTX detiene ora cinque brevetti concessi negli Stati Uniti e/o nell'UE, che coprono composizioni e utilizzi di agenti per la riduzione dell'acido urico nel trattamento della gotta, delle conseguenze dell'iperuricemia e delle malattie renali progressive.
XORTX Therapeutics (NASDAQ: XRTX) ha anunciado la concesión de una patente europea para las «Formulaciones de Inhibidores de la Xantina Oxidasa». La patente cubre composiciones y métodos para formular las exclusivas formulaciones XOI de la compañía, destinadas a tratar condiciones relacionadas con altos niveles de ácido úrico, incluyendo gota, enfermedades renales y cardiovasculares.
Esta patente fortalece la cartera de propiedad intelectual de XORTX en la UE y proporciona una protección más amplia para su programa innovador contra la gota y el programa de enfermedad renal poliquística autosómica dominante (ADPKD). La patente aborda específicamente las consecuencias para la salud derivadas de la formación de cristales de ácido úrico debido a la hiperuricemia.
Con esta incorporación, XORTX ahora posee cinco patentes concedidas en Estados Unidos y/o la UE, que cubren composiciones y usos de agentes reductores del ácido úrico para tratar la gota, las consecuencias de la hiperuricemia y la enfermedad renal progresiva.
XORTX Therapeutics (NASDAQ: XRTX)는 ‘잔틴 산화효소 억제제 제형’에 대한 유럽 특허 취득을 발표했습니다. 이 특허는 고요산혈증과 관련된 질환, 특히 통풍, 신장 및 심혈관 질환 치료를 위한 회사의 독자적인 XOI 제형의 조성물 및 제조 방법을 포함합니다.
이번 특허는 EU 내 XORTX의 지적 재산권 포트폴리오를 강화하며, 선도적인 통풍 치료 프로그램과 상염색체 우성 다낭성 신장질환(ADPKD) 프로그램에 대한 보다 광범위한 보호를 제공합니다. 이 특허는 고요산혈증으로 인한 요산 결정 형성에서 비롯되는 건강 문제를 구체적으로 다룹니다.
이번 특허 추가로 XORTX는 현재 미국 및/또는 EU에서 5건의 특허를 보유하고 있으며, 통풍, 고요산혈증의 결과 및 진행성 신장 질환 치료를 위한 요산 저감제의 조성물과 용도를 포함합니다.
XORTX Therapeutics (NASDAQ : XRTX) a annoncé l’octroi d’un brevet européen pour les « Formulations d’inhibiteurs de la xanthine oxydase ». Ce brevet couvre des compositions et des méthodes pour formuler les formulations propriétaires XOI de la société, destinées au traitement des affections liées à un taux élevé d’acide urique, notamment la goutte, les maladies rénales et cardiovasculaires.
Ce brevet renforce le portefeuille de propriété intellectuelle de XORTX dans l’UE et offre une protection élargie pour leur programme innovant contre la goutte ainsi que pour le programme de maladie polykystique autosomique dominante du rein (ADPKD). Le brevet traite spécifiquement des conséquences sanitaires résultant de la formation de cristaux d’acide urique due à l’hyperuricémie.
Avec cet ajout, XORTX détient désormais cinq brevets délivrés aux États-Unis et/ou dans l’UE, couvrant des compositions et utilisations d’agents abaissant l’acide urique pour le traitement de la goutte, des conséquences de l’hyperuricémie et des maladies rénales progressives.
XORTX Therapeutics (NASDAQ: XRTX) hat die Erteilung eines europäischen Patents für „Xanthinoxidase-Inhibitor-Formulierungen“ bekanntgegeben. Das Patent umfasst Zusammensetzungen und Methoden zur Formulierung der firmeneigenen XOI-Formulierungen zur Behandlung von Erkrankungen im Zusammenhang mit hohem Harnsäurespiegel, einschließlich Gicht, Nieren- und Herz-Kreislauf-Erkrankungen.
Dieses Patent stärkt das geistige Eigentumsportfolio von XORTX in der EU und bietet einen erweiterten Schutz für ihr wegweisendes Gichtprogramm sowie das autosomal-dominante polyzystische Nierenerkrankungsprogramm (ADPKD). Das Patent befasst sich speziell mit den gesundheitlichen Folgen, die durch die Bildung von Harnsäurekristallen infolge von Hyperurikämie entstehen.
Mit dieser Ergänzung hält XORTX nun fünf erteilte Patente in den USA und/oder der EU, die Zusammensetzungen und Anwendungen von harnsäuresenkenden Wirkstoffen zur Behandlung von Gicht, den Folgen von Hyperurikämie und fortschreitenden Nierenerkrankungen abdecken.
- Secured new European patent strengthening IP portfolio
- Patent covers multiple treatment applications including gout and ADPKD
- Expands commercialization and partnering opportunities in Europe
- Company now holds 5 granted patents in US and/or EU markets
- None.
Insights
XORTX's new European patent strengthens IP portfolio, protecting proprietary XOI formulations across major markets and multiple disease applications.
XORTX has secured a significant expansion of its intellectual property portfolio with the European Patent Office's decision to grant the "Xanthine Oxidase Inhibitor Formulations" patent. This European patent specifically protects the company's proprietary formulations of xanthine oxidase inhibitors for treating conditions related to chronically high uric acid levels.
The patent grant provides critical market exclusivity in the European Union for XORTX's technology platform. This augments their existing patents, bringing their total to five granted patents across the US and EU markets - a substantial intellectual property foundation for a company with a
From a strategic perspective, this patent demonstrates comprehensive protection across two major pharmaceutical markets. The breadth of the patent is particularly noteworthy, covering multiple potential applications including gout, kidney stone formation, and cardiovascular disease. This multi-indication coverage creates several possible development and commercialization pathways.
For pharmaceutical companies, especially those in clinical development stages, robust patent protection is fundamental to their business model. This patent specifically strengthens XORTX's position for their key therapeutic programs in gout and autosomal dominant polycystic kidney disease (ADPKD), potentially making these programs more attractive for future commercialization or partnership opportunities.
European patent grant enhances XORTX's competitive positioning in gout and kidney disease therapeutics, creating multiple potential commercialization pathways.
This European patent grant represents a meaningful development for XORTX's therapeutic programs targeting gout and ADPKD. The patent specifically protects their proprietary XOI formulations, which form the foundation of their platform technology.
The granted patent specifically addresses novel therapeutics for uric acid crystal formation resulting from hyperuricemia, positioning XORTX in a specialized niche within broader disease markets. The CEO's reference to their gout program as "first-in-class" suggests potential differentiation from existing treatment approaches, though clinical validation remains essential.
For a late-stage clinical pharmaceutical company with XORTX's profile, intellectual property protection is crucial for maintaining competitive positioning. This European patent complements their existing US patents, creating a more comprehensive global protection strategy for their core technology.
The patent's coverage across multiple indications—including gout, kidney stone formation, and cardiovascular disease—provides XORTX with flexibility in their development pathway. This could potentially allow them to pursue the most promising clinical applications based on their ongoing development program results.
While patents are just one component of pharmaceutical development success, which ultimately depends on clinical trial outcomes and regulatory approvals, this patent grant represents a positive step in de-risking XORTX's development programs by securing market protections for any successfully developed therapies.
Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs
CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease , is pleased to announce receipt of notification that the patent “Xanthine Oxidase Inhibitor Formulations” will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors (“XOI”) for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other diseases where aberrant purine metabolism has been implicated in disease progression.
Dr. Allen Davidoff, CEO of XORTX stated, “This patent covers compositions of formulations key to XORTX’s platform technology and this issuance strengthens our intellectual property portfolio in the European Union (“EU”). Importantly, this European patent broadens protection of our first-in-class program for gout as well as supporting our autosomal dominant polycystic kidney disease (“ADPKD”) program. This patent focuses on the health consequences that arise from uric acid crystal formation due to hyperuricemia in conditions including gout, kidney stone formation, cardiovascular disease and covers novel therapeutic solutions developed specifically to address these problems. The granting of this patent provides additional breadth of patent to XORTX for commercialization and partnering opportunities throughout Europe. Including this newly granted patent, XORTX now has five granted patents in the United States (“US”) and/or EU covering compositions and uses of uric acid lowering agents to treat gout, the health consequences of hyperuricemia, and progressive kidney disease.”
About Hyperuricemia, Gout and Health Consequences
It is estimated that
Recent groundbreaking studies by Wang et al. suggests linkage of genetic factors to the overexpression of XO(1). Recently, emerging discoveries link genetic factors to specific populations and show that higher XO expression is associated with a variety of conditions including hyperuricemia(2), general sepsis, organ failure and sepsis associated with acute respiratory distress syndrome (ARDS)(3,4), kidney dysfunction(3,4), diabetes(5), polycystic kidney disease(1,5) and kidney failure(6,7). From a mechanistic standpoint, these studies advocate for a precision medicine approach in which genetic risk variants would guide treatment decisions(1).
Addressable Gout Market Opportunity
In North America, approximately 3.5 million people suffer from gout due to elevated uric acid levels in blood. The therapeutic options to lower uric acid levels include three major classes of drugs: 1) oral uricosurics that are used to decrease the reabsorption of uric acid by the kidney; 2) intravenous uricase enzymes that are used to metabolize uric acid in the blood for excretion; and 3) oral XOIs that are used to inhibit the production of uric acid by the purine metabolic pathway. XOIs are the preferred first-line treatment for gout. Allopurinol is the most commonly prescribed XOI, with approximately 3 million prescriptions written per year in North America, however 3 to
References:
- Korsmo HW, Emerging roles of xanthine oxidoreductase in chronic kidney disease, Antioxidants, June 2024
- Major TJ, et all, Evaluation of the diet wide contribution to serum urate levels: Met-analysis of population based cohorts, BMJ, 363, k3952, 2018
- Gao, Li et al., Xanthine oxidoreductase gene polymorphism are associated with high risk of sepsis and organ failure, Respir. Res, 24, 177_2023
- Liu H, et al., Genetic variants in XDH are associated with prognosis off gastric cancer in a Chines population, 663, 196, 2013
- Wang et al., Genetic susceptibility to diabetic kidney disease is linked to promoter variants of XOR,” The authors identified an expression quantitative trait loci (QTL) in the cis-acting regulatory region of the xanthine dehydrogenase, or xanthine oxidoreductase (XO), a binding site for C/EBPβ, to be associated with diabetes-induced podocyte loss in diabetic kidney disease in male mice. They concluded that certain types of alleles of a gene that controls the expression of xanthine oxidase can be over expressed in CKD, diabetic kidney disease and polycystic kidney disease.
- Kudo M et al., Functional Characterization of Genetic Polymorphisms Identified in the Promotor Region of the Xanthine Oxidase Gene, Drug Metab. Pharmacokinet., 25, 599, 2010
- Boban M, et al., Circulating purine compound, uric acid, and xanthine oxidase/dehydrogenate relationship in essential hypertension and end stage renal disease., Ren. Fail., 36, 613, 2014
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
| adavidoff@xortx.com or +1 403 455 7727 | nick@alpineequityadv.com or +1 617 901 0785 |
Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
1 Source: Takeda Pharmaceutical Company 2018 Annual Report.
FAQ
What is the significance of XORTX's new European patent for its gout treatment program?
How many patents does XORTX (XRTX) now hold in the US and EU markets?
What medical conditions will XORTX's patented XOI formulations target?
How does XORTX's new European patent impact their ADPKD program?
